Tesamorelin
A GHRH analogue that targets deep visceral fat.
iThe essentials in 10 seconds
- GHRH analogue — stimulates natural growth hormone
- Mainly targets visceral fat (deep abdominal fat)
- The only treatment in this family approved for its primary indication
- Daily subcutaneous injection, under medical supervision
IWhat is Tesamorelin?
Tesamorelin is a GHRH analogue that stimulates growth hormone secretion. Its benefit: it specifically reduces visceral fat — the deep fat around the organs, linked to cardiometabolic risk — where diet has less effect. It is approved for HIV-associated lipodystrophy and studied in steatosis and metabolic syndrome.
Highly regulated medication, requiring strict prescription and monitoring (IGF-1, blood glucose). Apart from its primary indication, evidence remains limited.
The molecules presented on this site are innovative and fall under experimental use. Human data remain limited: a studied mechanism or a preclinical observation is not sufficient to demonstrate a benefit. The regulatory status in Morocco is not established for most of these peptides. Any use is decided within the framework of a medical consultation, with follow-up — never alone, never without an assessment.
IIThe benefits
Reduces deep abdominal fat surrounding the organs, linked to cardiometabolic risk.
Decreases waist circumference, a simple marker of metabolic risk.
Increases energy expenditure and fat oxidation.
Overall goal: triglycerides, inflammation, insulin sensitivity.
Area of interest in non-alcoholic fatty liver disease (studies).
Unlike many treatments, preserves lean mass.
IIIRecommendations & how to use
Route: subcutaneous injection (abdomen) · Frequency: daily, at a regular time · Storage: refrigerated (2–8 °C).
Treatment under medical supervision (IGF-1, blood glucose, tolerability).
| Dosage | Price |
|---|---|
| 10 mg | Provided on request |
Prices are not published online: they are provided on request, during a consultation or by telephone.
IVThe two protocols
Goal: reduce visceral fat and waist circumference.
Monitoring: waist circumference, IGF-1, tolerability (injection site pain, blood glucose).
Goal: improve body composition and metabolic profile.
Combine with: physical activity and dietary habits; the peptide is an adjunct.
VProtocol rules
- Controlled diet (refined sugars, alcohol)
- Regular physical activity
- Record waist circumference and how you feel
- Comply with laboratory monitoring
- Store vials in the refrigerator
- Never self-medicate: prescription-only treatment
- Do not exceed the dose
- Vary injection sites (local pain)
- Do not continue without reassessment
- Pregnancy, breastfeeding, active tumor: contraindication
VIYour journey in 3 steps
Metabolic evaluation, contraindications, workup (IGF-1, blood glucose), protocol provided.
1 injection/day, monitoring of waist circumference and tolerability.
Laboratory and metabolic workup, decision on next steps.
VIISide effects & level of evidence
- Arthralgia, myalgia
- Injection-site reaction
- Raised IGF-1 and blood glucose
- Fluid retention
- Pregnancy, breastfeeding
- Active malignancy
- Hypersensitivity
- Diabetes: close monitoring
Non-exhaustive list based on the available literature and known class effects; it replaces neither a product label nor an individual medical assessment.
VIIIPublications & references
- Tesamorelin · · 2012 · PMID 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophySpooner LM, Olin JL · Ann Pharmacother · 2012 · PMID 22298602
- TesamorelinGrunfeld et al. · Nat Rev Drug Discov · 2011 · PMID 21283099
Documentary references: the existence of a publication establishes neither efficacy nor safety for personal use. The regulatory status in Morocco must be verified.